The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
Despite overcast weather a large crowd joined veterans and gathered around Dunkirk's memorial square to pay their respects.
A German 65-year-old teacher from Berlin has given birth to quadruplets after a pregnancy that was widely criticised because of her age.
Although there are bright skies for many as we start the bank holiday, more central, eastern and south eastern regions will be cloudy.